
Recurrent Clostridioides difficile Infection (rCDI) - Pipeline Insight, 2024
Description
Recurrent Clostridioides difficile Infection (rCDI) - Pipeline Insight, 2024
DelveInsight’s, “Recurrent Clostridioides difficile Infection (rCDI) - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Recurrent Clostridioides difficile Infection (rCDI) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Recurrent Clostridioides difficile Infection (rCDI): Overview
Clostridioides difficile is a gram-positive bacterium that is the cause most implicated in antibiotic-associated diarrhea. The emergence of a newer hypervirulent strain North American pulsed-field gel electrophoresis type 1 (NAP1) has been attributed to the increase in incidence and severity of C. difficile infections (CDI) over the last decade. C. difficile colonizes in the large intestine of humans. Healthy adults with adequate immune response become asymptomatic carriers of the disease. Neonates also have a high rate of asymptomatic carrier rate, owing to a lack of intestinal receptors for C. difficile. The use of antibiotics alters the microbial flora of the large intestine, rendering it susceptible to infection by C. difficile, and the transmission of the disease occurs through the fecal-oral route.
""Recurrent Clostridioides difficile Infection (rCDI) - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Recurrent Clostridioides difficile Infection (rCDI) pipeline landscape is provided which includes the disease overview and Recurrent Clostridioides difficile Infection (rCDI) treatment guidelines. The assessment part of the report embraces, in depth Recurrent Clostridioides difficile Infection (rCDI) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence in Recurrent Clostridioides difficile Infection (rCDI) R&D. The therapies under development are focused on novel approaches to treat/improve in Recurrent Clostridioides difficile Infection (rCDI).
Recurrent Clostridioides difficile Infection (rCDI) Emerging Drugs
- RBX7455: Rebiotix
Further product details are provided in the report……..
Recurrent Clostridioides difficile Infection (rCDI): Therapeutic Assessment
This segment of the report provides insights about the different Recurrent Clostridioides difficile Infection (rCDI) drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Recurrent Clostridioides difficile Infection (rCDI)
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Recurrent Clostridioides difficile Infection (rCDI): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Recurrent Clostridioides difficile Infection (rCDI) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Recurrent Clostridioides difficile Infection (rCDI) drugs.
Recurrent Clostridioides difficile Infection (rCDI) Report Insights
- Recurrent Clostridioides difficile Infection (rCDI) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Recurrent Clostridioides difficile Infection (rCDI) drugs?
- How many Recurrent Clostridioides difficile Infection (rCDI) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Recurrent Clostridioides difficile Infection (rCDI)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Recurrent Clostridioides difficile Infection (rCDI)?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Recurrent Clostridioides difficile Infection (rCDI) and their status?
- What are the key designations that have been granted to the emerging drugs?
- Vedanta Biosciences
- Rebiotix
- Takeda
- Adiso Therapeutics
- Lumen Bioscience
- RBX7455
- VE303
- VP20621
- ART24
- LMN201
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Recurrent Clostridioides difficile Infection (rCDI) : Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Recurrent Clostridioides difficile Infection (rCDI) – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- RBX 7455: Rebiotix
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- VP20621: Takeda
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- ADS 024: Adiso Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Recurrent Clostridioides difficile Infection (rCDI) Key Companies
- Recurrent Clostridioides difficile Infection (rCDI) Key Products
- Recurrent Clostridioides difficile Infection (rCDI) - Unmet Needs
- Recurrent Clostridioides difficile Infection (rCDI) - Market Drivers and Barriers
- Recurrent Clostridioides difficile Infection (rCDI) - Future Perspectives and Conclusion
- Recurrent Clostridioides difficile Infection (rCDI) Analyst Views
- Recurrent Clostridioides difficile Infection (rCDI) Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.